Analysts have been eager to weigh in on the Healthcare sector with new ratings on Actinium Pharmaceuticals (NYSE:ATNM), Rocket Pharmaceuticals Inc (NASDAQ:RCKT) and Radius Health (NASDAQ:RDUS).
Actinium Pharmaceuticals (ATNM)
Maxim Group analyst Jason McCarthy maintained a Buy rating on Actinium Pharmaceuticals today and set a price target of $3. The company’s shares opened today at $0.75.
McCarthy wrote:
“Novartis (NVS – NR) announced plans to acquire Endocyte (ECYT – and expand its radiolabeled pharmaceuticals platform (RLP); picking up for prostate cancer which is currently in a P3 trial. In our view, this should bode well for Actinium.”
According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 13.1% and a 51.7% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
Actinium Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $4.25, a 466.7% upside from current levels. In a report issued on October 10, Roth Capital also maintained a Buy rating on the stock with a $6 price target.
.
See today’s analyst top recommended stocks >>
Rocket Pharmaceuticals Inc (RCKT)
Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Rocket Pharmaceuticals Inc today. The company’s shares opened today at $21.23.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 10.1% and a 51.7% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals Inc, Alexion Pharmaceuticals, and Vertex Pharmaceuticals.
Rocket Pharmaceuticals Inc has an analyst consensus of Moderate Buy.
Radius Health (RDUS)
Cowen & Co. analyst Chris Shibutani maintained a Hold rating on Radius Health today. The company’s shares opened today at $19.87, close to its 52-week low of $16.71.
According to TipRanks.com, Shibutani is a 3-star analyst with an average return of 5.5% and a 39.1% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Pieris Pharmaceuticals, Nektar Therapeutics, and United Therapeutics.
Currently, the analyst consensus on Radius Health is a Hold with an average price target of $25.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
